DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Current Status of 18/876,991
This Office Action is responsive to the amended claims of 12/19/2024. Claims 1-15 are pending and have been examined on the merits.
Priority
The instant application is a national stage entry of PCT/US2023/069482, filed 06/30/2023, which claims priority to U.S. Provisional Patent Application No. 63/357,826, filed 07/01/2022.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 03/18/2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Drawings
The drawings are objected to because FIG 3A and FIG 3B are illegible. Each figure contains overlapping plots for seven different compounds, wherein the black-and-white lines representing the respective compounds are indistinguishable from one another. As a result, the figures are unreadable in their current form and do not permit meaningful differentiation or comparison of the compounds and their respective properties. The Examiner suggests presenting the data for each of the seven compounds in separate plots, using consistent axes and scales. Such a presentation would improve legibility and facilitate clear comparison of the exhibited properties of the compounds. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-3, 6, and 10-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 1-3 are drawn to compounds of Formulae (I), (II), and (III). Each of these compounds’ structures fail to define the structure of the flexible linker and allosteric moiety attached at the 17-nitrogen
PNG
media_image1.png
215
322
media_image1.png
Greyscale
. The current representations of the claimed compounds does not indicate that X or R1 are bound to the alkylene groups and instead appear as -X and -R1. The following is a suggested structure that clearly shows what the Examiner believes is the intended connectivity of moiety attached at the 17-nitrogen
PNG
media_image2.png
381
518
media_image2.png
Greyscale
. This structure clearly shows the connectivity of X and R1 to the alkylene groups. The structures of Formulae (II) and (III) should be corrected in a similar fashion to accurately reflect the desired connectivity.
Claim 6 recites the limitation "wherein R1 is –NRb(C=NRb)N(Rb)2" in line 1 of the claim. There is insufficient antecedent basis for this limitation in the claim because the compound of Formula (I), as depicted in claim 1, does not establish a covalent bond connecting the R1 group to the alkylene moiety attached at the 17-nitrogen.
Claim 10 recites the limitation "wherein X is CH2" in line 1 of the claim. There is insufficient antecedent basis for this limitation in the claim because Formula (I) does not establish a covalent bond connecting the X group to the alkylene moiety attached at the 17-nitrogen.
Claim 11 recites the limitation "wherein X is
PNG
media_image3.png
83
323
media_image3.png
Greyscale
" in lines 1-2 of the claim. There is insufficient antecedent basis for this limitation in the claim because Formula (I) does not establish a covalent bond connecting the X group to the alkylene moiety attached at the 17-nitrogen.
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 1 recites the broad recitation n is an integer from 0 to 8, and the claim also recites n is 5 which is the narrower statement of the range/limitation. The claim is considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 15 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating pain comprising administering certain compounds of Formula (I) (the compounds of claims 12 and 13), does not reasonably provide enablement for a method of treating pain comprising any compound of Formula (I). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in Wands states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not ‘experimentation’” (Wands, 8 USPQ2sd 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (Wands, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. While all of these factors are considered, a sufficient amount for a prima facie case is discussed below.
(1) The nature of the invention and (2) the breadth of the claims:
The claims are drawn to a method of treating pain comprising administering a compound of Formula (I) to a patient suffering from pain. The substituent attached at the 17-nitrogen encompass hundreds of thousands of potential structural combinations based solely on the recited alternatives for m, n, X1, R1, and Rb. The scope is even broader than this when considering the full scope of Rb, which encompasses any substituted phenyl and any protecting group. The scope of the claimed compounds is further expanded when considering the encompassed substitutions of R2-R5 and J1-J2. Thus, the claims taken together with the specification imply that any compound of Formula (I) is capable of treating pain. The scope of the claims is extremely broad.
(3) The state of the prior art and (4) the predictability or unpredictability of the art:
The prior art teaches that naltrindole (NTI) is a DOR antagonist. Nemoto et al. ((Nemoto, Toru, et al. "Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists." Bioorganic & Medicinal Chemistry Letters 25.15 (2015): 2927-2930., found in IDS filed 03/18/2025) disclose NTI derivatives of Formulae 4a-e and 6a-e with the following structures
PNG
media_image4.png
109
314
media_image4.png
Greyscale
(Table 1). The reference teaches substitutions a the 17-nitrogen position (R group), but the substitutions are limited to C2-C3 alkyl and haloalkyl groups (Table 1). These relatively minor changes to the group at the 17-nitrogen position result in substantial differences in receptor binding affinity, selectivity, and pharmacological activity (Abstract). These findings demonstrate that relatively minor structural modifications can produce substantial and unpredictable changes in the pharmacological properties of the DOR ligands.
The teachings of Nemoto et al. demonstrate the high degree of unpredictability associated with modifications at the 17-nitrogen position of opioid receptor ligands.
(5) The relative skill of those in the art:
The artisan would have experience in the field of organic chemistry, medicinal chemistry, pharmaceutical sciences, or a related field. The artisan would have experience in the design, synthesis, and biological evaluation of small-molecule compounds that target opioid receptors for the treatment of pain. The artisan would be familiar with pharmacological assays for evaluating opioid receptor binding affinity, including assays measuring receptor agonism, G-protein signaling, and b-arrestin recruitment.
(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:
The specification has provided guidance for the synthesis of compounds of Formula (I) and characterization of certain compounds of Formula (I), including intermediate species (pg. 24, line 15 – pg. 50 line 9), pharmaceutical dosage forms for the compounds of Formula (I) (pg. 50 line 11 – pg. 52 line 10). The specification further provides BRET assay data evaluating the activity of the compounds of instant claims 12 and 13 at the delta (DOR), kappa (KOR), and mu (MOR) opioid receptors, relative to the respective reference agonists DPDPE, U50488, and DAMGO.
However, the specification does not provide corresponding biological assay data for the furan-containing compounds of instant claim 14 or for the full scope of compounds encompassed by Formula (I). The compounds evaluated in the disclosed assays are limited to structures bearing flexible alkylene linkers terminating in guanidine groups. Accordingly, the experimental results do not establish the opioid receptor activity of compounds having alternative linkers and/or terminal functional groups encompassed by Formula (I).
(8) The quantity of experimentation necessary:
Considering the state of the art as discussed by the references above, particularly with regards to the substantial effects of minor structural changes to the 17-nitrogen substituent on opioid binding affinity, selectivity, and functional activity and the high unpredictability in the art as evidenced therein, and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention commensurate in the scope of the claims.
Close Art
The prior art of record does not teach the compounds of the instant invention. Specifically, the prior art does not teach the instantly claimed moiety with the specific groups required by the instant invention at the 17-nitrogen position. The closest prior art is Nemoto et al. (Nemoto, Toru, et al. "Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists." Bioorganic & Medicinal Chemistry Letters 25.15 (2015): 2927-2930., found in IDS filed 03/18/2025). Nemoto et al. disclose derivatives of the DOR agonist naltrindole (NTI) of Formulae 4a-e and 6a-e with the following structures
PNG
media_image4.png
109
314
media_image4.png
Greyscale
(Table 1). The reference teaches substitutions at the 17-nitrogen position (R group), but the substitutions are limited to C2-C3 alkyl and haloalkyl groups (Table 1). These relatively minor changes to the group at the 17-nitrogen position results in substantial differences in receptor binding affinity, selectivity, and pharmacological activity (Abstract). These findings demonstrate that relatively minor structural modifications can produce substantial and unpredictable changes in the pharmacological properties of the DOR ligands. Based on this disclosure, the artisan would not have reasonably expected that the instantly claimed compounds would exhibit the requisite binding affinities and pharmacological activities at the targeted opioid receptors, given the unpredictable effects imparted by relatively minor structural modifications to the compounds.
Conclusion
Claims 1-3, 6, 10-11, and 15 are rejected.
Claims 4-5, 7-9, and 12-14 are objected to for being dependent upon a rejected base claim.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CONNOR KENNEDY ENGLISH whose telephone number is (571)270-0813. The examiner can normally be reached Monday Friday, 8 a.m. 5 p.m. ET..
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571)272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/C.K.E./Examiner, Art Unit 1625 /Andrew D Kosar/Supervisory Patent Examiner, Art Unit 1625